PARIS, May 23, 2018 — Institut Curie and Intel initiate a pioneering collaboration to develop, use and implement innovative bioinformatics tools, pipelines and techniques to improve the use of molecular profiling across both research and clinical oncology settings.

On Wednesday, Intel CEO Brian Krzanich met with French Président Emmanuel Macron during the Tech For Good Summit in Paris. Deeply conscious of what technology and artificial intelligence (AI) can do for the economy and society and with an unprecedented assembly of tech leaders from across the globe, the summit aims to establish the world’s foremost venue for frank and open conversations about technology’s central role in the modern world. The summit was the opportunity for Krzanich to discuss the new collaboration with the French Institut Curie around use of artificial intelligence to provide personalized cancer treatment.

Read the Intel press release.

Learn more about Institut Curie.

Penn Medicine operates a network of healthcare facilities in Pennsylvania and southern New Jersey. Penn Medicine has worked with Intel to create a collaborative open source data science platform called Penn Signals* that can help clinicians make faster, smarter decisions based on large-scale clinical data and big data.

The first trials of the platform covered two of the most common and costly issues for hospitals: sepsis and heart failure. In the case of sepsis, the pilot was able to improve its identification of cases from 50 percent to 85 percent, and improve identification time before the onset of septic shock from 2 to 30 hours.

For heart failure patients, the algorithm provided Penn Medicine’s clinical team with its first accurate measure of the quantity and distribution of sufferers. Using standard diagnostic tools, 20–30 percent of heart failure patients had not been properly identified. With the predictive model, these patients could be identified and given education to self-manage their condition, leading to a marked decrease in readmission rates.

Read the whitepaper.

Learn more about Penn Medicine.

Visit Penn Signals on GitHub.

Advances in Big Data Analytics are giving cancer researchers powerful new ways to extract value from diverse sources of data. UNICANCER, one of Europe’s largest cancer research organizations, has demonstrated a next-generation data analytics solution with the potential to improve clinical trials, health economics, clinician/researcher productivity, and patient care. The solution — called Continum Soins Recherche (ConSoRe*) or Continuum of Care Research — has been deployed as a pilot across four UNICANCER sites:

· Centre Georges François Leclerc (CGFL) in Dijon

· Centre Léon Bérard (CLB) in Lyon

· Institut Curie in Paris

· Institut du Cancer de Montpellier (ICM) in Montpellier

Read the whitepaper.

En savoir plus: http://www.unicancer.fr/recherche/consore-moteur-recherche-pour-big-data-en-cancerologie

For hospital administrators, predicting the number of patient visits to emergency departments, along with their admission rates, is critical for optimizing resources at all levels of staff. Ultimately, this reduces wait times in emergency departments and improves the quality of patient care.

Intel and the Assistance Publique-Hôpitaux de Paris (AP-HP), the largest university hospital in Europe, worked together to build a cloud-based solution for predicting the expected number of patient visits and hospital admissions using advanced data science methodologies and the Trusted Analytics Platform (TAP). TAP is an open source platform that accelerates the creation of applications driven by big data analytics. Using data from four emergency departments within AP-HP, data scientists from Intel and medical experts from AP-HP evaluated three different approaches to time series analytics, optimizing model parameters and identifying the best predictive features to include in each.

Read the whitepaper.

See Forbes coverage, “Big Data In Healthcare: Paris Hospitals Predict Admission Rates Using Machine Learning“.

Learn more about Assistance Publique-Hôpitaux de Paris (AP-HP)